LYOPHILISATE BASED ON PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS FOR PREPARING A RADIOPHARMACEUTICAL COMPOSITION IN FORM OF SOLUTION FOR INJECTIONS FOR TREATING PROSTATE CANCER, RADIOPHARMACEUTICAL COMPOSITION BASED ON IT FOR TREATING PROSTATE CANCER AND METHOD FOR PREPARING RADIOPHARMACEUTICAL COMPOSITION Russian patent published in 2024 - IPC A61K9/19 A61K47/12 A61K47/26 A61K51/04 A61P35/00 

FIELD: chemistry; pharmaceutics.

SUBSTANCE: group of inventions relates to chemistry and pharmaceutical industry, more specifically to the field of creating radiopharmaceutical preparations. Disclosed are: a lyophilisate based on ligands to a prostate-specific membrane antigen (PSMA) for preparing a radiopharmaceutical composition, containing 0.1 mg of a PSMA I&T precursor, 20 mg of sodium acetate, 5 mg of gentisic acid, 1 mg of mannitol; radiopharmaceutical composition in the form of a solution for injections for treating prostate cancer, having pH of 4.0–6.3 and includes (per 1 ml) active substance ¹⁷⁷Lu in form of complex of ¹⁷⁷Lu-PSMA I&T with volume activity of 250–6,000 MBq/ml and excipients such as sodium acetate (10 mg), gentisic acid (2.5 mg) and mannitol (0.5 mg); as well as a method for preparing said radiopharmaceutical composition from the disclosed lyophilisate.

EFFECT: group of inventions provides a wider range of effective and safe radiopharmaceuticals for targeted radionuclide therapy of castration-resistant cancer.

3 cl, 9 tbl, 3 ex